Other substances

Myricetin

A natural flavone.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Natural product

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Myricetin is a natural flavone compound isolated from various plant species. It has antineoplastic, antioxidant and cyclooxygenase 1 inhibitor activities (ChEBI).

Myricetin on DrugBank
Myricetin on PubChem
Myricetin on Wikipedia

C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies Screening	in silico	6.71	Predicted to bind the SARS-CoV-2 spike protein or spike protein:ACE2 interface.	Aug/05/2020
In-silico screening of plant-derived antivirals against main protease, 3CLpro and endoribonuclease, NSP15 proteins of SARS-CoV-2 3CLpro nsp15 Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 3C-like protease and the nsp15 endoribonuclease.	Sep/08/2020
Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study Spike protein 3CLpro Small molecule In silico Screening	in silico	3.22	Predicted to bind to the SARS-CoV-2 spike protein.	Sep/18/2020
An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2 nsp15 Small molecule In silico	in silico	6.31	Predicted to inhibit the SARS-CoV-2 endoribonuclease (nsp15).	Dec/28/2020
Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay; Vero cells; HEK293T cell lysates; SARS-CoV-2 isolate C-Tan-nCoV Wuhan strain 01	4.31	Inhibits SARS-CoV-2 3C-like protease in vitro with IC50 of 2.86 µM.	Jan/04/2021

AI-suggested references

Link	Publication date
Combined molecular docking and dynamics simulations studies of natural compounds as potent inhibitors against SARS-CoV-2 main protease.	Jul/27/2021
Discovery of Some Antiviral Natural products to fight against Novel Corona Virus (SARS-CoV-2) using Insilico approach.	Dec/22/2021
Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2.	Jun/11/2021
Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19.	Nov/21/2020
In silico screening of phytopolyphenolics for the identification of bioactive compounds as novel protease inhibitors effective against SARS-CoV-2.	Jun/03/2020
In Silico Studies Reveal Antiviral Effects of Traditional Indian Spices on COVID-19.	Dec/29/2020
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.	Jun/15/2021
Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease	May/27/2020
Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation.	Jun/17/2021
Computational Study of SARS-CoV-2 RNA Dependent RNA Polymerase Allosteric Site Inhibition	Jul/17/2020
Antiviral Activity of Vitis vinifera Leaf Extract against SARS-CoV-2 and HSV-1	May/28/2020
Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study	Mar/10/2021
Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2	Jul/24/2020
A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.	Jan/07/2021
Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.	Oct/29/2020
Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis	Jul/28/2020
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.	Mar/11/2021
Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.	Jul/21/2021
The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship	Mar/30/2021
Camphor, Artemisinin and Sumac Phytochemicals as inhibitors against COVID-19: Computational approach.	Aug/11/2021
Potential of Flavonoid-Inspired Phytomedicines against COVID-19	Jun/11/2020
Chemical constituents from Limonium tubiflorum and their in silico evaluation as potential antiviral agents against SARS-CoV-2	Sep/30/2021
Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CLpro.	Dec/23/2020
Natural product-derived phytochemicals as potential agents against coronaviruses: A review	Apr/30/2020
Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites.	Dec/11/2020
Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus	Oct/20/2020
Inhibition of SARS-CoV-2 main protease by phenolic compounds from Manilkara hexandra (Roxb.) Dubard assisted by metabolite profiling and in silico virtual screening	Apr/17/2022
Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease in vitro.	Oct/08/2021
Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities.	Apr/01/2022
Delineating a potent antiviral activity of Cuphea ignea extract loaded nano-formulation against SARS-CoV-2: In silico and in vitro studies	Sep/15/2021
Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants	Nov/30/2020

Export (.csv)